tbuckley/cabot-search huggingface dataset:
AI Based CMR Assessment of Biventricular Function
Authors: Shuo Wang, Hena Patel, Tamari Miller, Keith Ameyaw, Akhil Narang, Daksh Chauhan, Simran Anand, Emeka Anyanwu, Stephanie A. Besser, Keigo Kawaji, Xing-Peng Liu, Roberto M. Lang, Victor Mor-Avi, Amit R. Patel
Journal: JACC. Cardiovascular imaging (2021)
Abstract 024: Trends in Anatomical Location and Case Fatality of Myocardial Infarction in Four US Communities, 1987–2008: The Atherosclerosis Risk in Communities (ARIC) Study
Authors: Jonathan D Newman, Daichi Shimbo, Chris Baggett, Xiaoxi Liu, Richard Crow, Laura R Loehr, Aaron R Folsom, Wayne D Rosamond
Journal: Circulation (2012)

INTRODUCTION: Although the incidence of and mortality following ST-segment elevation MI (STEMI) is decreasing, time-trends in STEMI infarct location and associated prognosis have not been examined in a population-based community study. METHODS: We determined 22-year trends in age-adjusted, gender-specific incident hospitalized STEMI and 28-day case fatality among 35–74 year old residents of four ARIC surveillance study communities. STEMI location was assessed by 12-lead electrocardiograms (ECG) from hospital records and was coded as anterior (V2-V5), inferior (II, III, AVF), lateral (I, AVL, V6 alone or with V2-V5) or multiple (2 or more regions) infarct locations using Minnesota coding. Case fatalities were confirmed with linkage to the National Death Index. RESULTS: From 1987 to 2008, there were an estimated 6,108 (fatal or non-fatal) hospitalized STEMIs, with an average annual decrease of −4.0% (95% CI, −4.7, −3.3) in men and −3.1% (95% CI −4.1, −2.1) in women. By infarct location, 37.2% of STEMIs were inferior; 32.8% anterior; 16.8% multiple territories; and 13.2% lateral. Annually, inferior STEMI decreased by −1.5% (95% CI −2.4, −0.6) while STEMI in multiple infarct regions increased by 2.9% (95% CI 1.9, 4.3), Figure. The 28-day case fatality for anterior, inferior and lateral STEMI decreased from 10.9% (95% CI 7.9, 13.9) to 5.1% (95% CI 3.0, 7.2), P &lt; 0.01; from 6.1% (95% CI 4.5, 7.6) to 3.5% (95% CI 2.0, 5.0), P = 0.03; and from 14.8% (95% CI 8.6, 21.1) to 6.3% (95% CI 3.0, 9.6), P = 0.01, respectively. In contrast, no significant change in 28-day case fatality for STEMI in multiple infarct regions was observed. CONCLUSION: Between 1987 and 2008, significant heterogeneity by infarct location was observed for incident STEMI and in 28-day mortality after STEMI. In contrast to STEMI in other infarct locations, the proportion of STEMI involving multiple infarct territories increased over 22 years of surveillance, without improvement in 28-day mortality. These findings may have implications for STEMI surveillance and management.
COVID-19 outbreak among French firefighters, Marseille, France, 2020
Authors: Guillaume André Durand, Franck de Laval, Albane de Bonet d’Oléon, François Xavier Le Flem, Yann Morin, Cyril Badaut, Gilda Grard, Constance Brossier, Marion Fossier, Aissata Dia, Flavie Letois, Manon Geulen, Géraldine Piorkowski, Jean-Baptiste Meynard, Frank Peduzzi, Isabelle Leparc-Goffart, Vincent Pommier de Santi
Journal: Eurosurveillance (2021)

We investigated a COVID-19 outbreak at a fire station in Marseille, France. Confirmed cases were defined as individuals with positive SARS-CoV-2 reverse transcription (RT)-PCR and/or neutralising antibodies. All 85 firefighters at work during the outbreak period were included after questioning and sampled for RT-PCR and viral neutralisation assay. Twenty-three firefighters were confirmed positive, 19 of them were symptomatic, and four asymptomatic cases were confirmed by virus neutralisation. A total of 22 firefighters had specific neutralising antibodies against SARS-CoV-2. Neutralising antibodies were found in four asymptomatic and 18 symptomatic cases. Eleven symptomatic cases had high titres (≥ 1:80). The earliest detection of neutralising antibodies was 7 days after symptom onset, and 80% had neutralising antibodies 15 days after onset. One viral culture was positive 13 days after onset. The attack rate was 27%. We identified two introductions of the virus in this outbreak, through a presymptomatic and a paucisymptomatic case. Asymptomatic cases were not the source of a third generation of cases, although they worked without wearing a mask, indicating that asymptomatic cases did not play a significant role in this outbreak. Management and strategy based on early research of clinical signs associated with self-quarantine was effective.
High‐quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population
Authors: Eduardo Vilar‐Gomez, Lauren D. Nephew, Raj Vuppalanchi, Samer Gawrieh, Andrea Mladenovic, Francis Pike, Niharika Samala, Naga Chalasani
Journal: Hepatology (2021)

The effects of diet quality (DQ), physical activity (PA), and socioeconomic status (SES) on the risk of NAFLD are unclear. We examined the association among DQ, PA, SES, and NAFLD risk.
MA06.06 Treatment Recommendations for Stage III NSCLC by 3 Dutch Multidisciplinary Tumor Boards Prior To, and Following the PACIFIC Trial
Authors: M. Ronden, I. Bahce, N. Claessens, N. Barlo, M. Dahele, J. Daniels, C. Tissing-Tan, E. Hekma, S.M.S. Hashemi, A. Van Der Wel, F. Spoelstra, W. Verbakel, M. Tiemessen, M. Van Laren, A. Becker, S. Tarasevych, C. Haasbeek, K. Maassen Van Den Brink, C. Dickhoff, S. Senan
Journal: Journal of Thoracic Oncology (2021)
Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab and Remission Induction in ANCA-Associated Vasculitis—Reply
Authors: Shunsuke Furuta, Kei Ikeda, Hiroshi Nakajima
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomised trial of the P2X<sub>3</sub> receptor antagonist sivopixant for refractory chronic cough
Authors: Akio Niimi, Junpei Saito, Tadashi Kamei, Masaharu Shinkai, Hiroyuki Ishihara, Mitsuaki Machida, Sayaka Miyazaki
Journal: European Respiratory Journal (2021)

The purinoceptor subtype P2X3 has been shown to have significant involvement in the cough reflex; the heterotrimer version of the purinoceptor (P2X2/3) has been implicated in taste disturbance. The most advanced clinical candidate antagonist gefapixant has low selectivity among P2X3 receptors and induced taste disturbance, whereas newly developed sivopixant has high selectivity towards P2X3versus P2X2/3.In a phase 2a, randomised, double-blind, placebo-controlled, crossover, multicentre study, adult patients with refractory or unexplained chronic cough received oral sivopixant 150 mg or placebo once daily for 2 weeks, followed by a 2-3-week washout period, and then crossed over to placebo or sivopixant for 2 weeks. Efficacy and safety of sivopixant were evaluated.Of 31 randomised patients, 15 in the sivopixant-first group and 15 in the placebo-first group completed the study. After 2 weeks of treatment, the placebo-adjusted ratios of the average hourly number of coughs to baseline during daytime (primary end-point) and over 24 h (secondary end-point) were -31.6% (p=0.0546) and -30.9% (p=0.0386), respectively. Sivopixant also improved health-related quality of life. Treatment-related adverse events occurred in 12.9% and 3.2% of patients during sivopixant and placebo administration, respectively. Mild taste disturbance occurred in two patients (6.5%) during sivopixant administration.Sivopixant reduced objective cough frequency and improved health-related quality of life, with a low incidence of taste disturbance, among patients with refractory or unexplained chronic cough.
P23.04 Serum Biomarkers Enhance Prognostic Value of Computed Tomography (CT) in Patients With Non-Small Cell Lung Cancer (NSCLC)
Authors: T. Muley, M. Schneider, M. Meister, M. Thomas, C. Heussel, M. Kriegsmann, S. Holdenrieder, B. Wehnl, V. Rolny, A. Mang, R. Gerber, F. Herth
Journal: Journal of Thoracic Oncology (2021)
Religious support for assisted dying: moral anchors are rooted outside faith traditions
Authors: Moshe Freedman, Aryeh Greenberg
Journal: BMJ (2021)

The assertion proffered by Romain and Carey—that religious opposition to doctor assisted dying “is not largely on theological grounds” and that “nothing in our religious texts opposes” it—is theologically flawed.1

The Torah (for example, Exodus 21:19) obligates us to care for those who are unwell, and the Talmud famously equates the saving of life with the saving of an entire world (Sanhedrin …
Immunological configuration of ovarian carcinoma: features and impact on disease outcome
Authors: Jitka Fucikova, An Coosemans, Sandra Orsulic, David Cibula, Ignace Vergote, Lorenzo Galluzzi, Radek Spisek
Journal: Journal for ImmunoTherapy of Cancer (2021)

Epithelial ovarian carcinoma (EOC) is a relatively rare malignancy but is the fifth-leading cause of cancer-related death in women, largely reflecting early, prediagnosis dissemination of malignant disease to the peritoneum. At odds with other neoplasms, EOC is virtually insensitive to immune checkpoint inhibitors, correlating with a tumor microenvironment that exhibits poor infiltration by immune cells and active immunosuppression. Here, we comparatively summarize the humoral and cellular features of primary and metastatic EOC, comparatively analyze their impact on disease outcome, and propose measures to alter them in support of treatment sensitivity and superior patient survival.
53P Expression of sodium-dependent phosphate transporter NaPi2b is downregulated in malignant ovarian tumors after neoadjuvant chemotherapy
Authors: A.K. Nurgalieva, S. Safina, E. Shakirova, V. Filonenko, V. Skripova, L. Bulatova, D. Savenkova, M. Bogdanov, R. Kiyamova
Journal: Annals of Oncology (2021)
Titin (TTN): from molecule to modifications, mechanics, and medical significance
Authors: Christine M Loescher, Anastasia J Hobbach, Wolfgang A Linke
Journal: Cardiovascular Research (2021)

Abstract The giant sarcomere protein titin is a major determinant of cardiomyocyte stiffness and contributor to cardiac strain sensing. Titin-based forces are highly regulated in health and disease, which aids in the regulation of myocardial function, including cardiac filling and output. Due to the enormous size, complexity, and malleability of the titin molecule, titin properties are also vulnerable to dysregulation, as observed in various cardiac disorders. This review provides an overview of how cardiac titin properties can be changed at a molecular level, including the role isoform diversity and post-translational modifications (acetylation, oxidation, and phosphorylation) play in regulating myocardial stiffness and contractility. We then consider how this regulation becomes unbalanced in heart disease, with an emphasis on changes in titin stiffness and protein quality control. In this context, new insights into the key pathomechanisms of human cardiomyopathy due to a truncation in the titin gene (TTN) are discussed. Along the way, we touch on the potential for titin to be therapeutically targeted to treat acquired or inherited cardiac conditions, such as HFpEF or TTN-truncation cardiomyopathy.
Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout
Authors: Jason C. Yam, Xiu Juan Zhang, Yuzhou Zhang, Yu Meng Wang, Shu Min Tang, Fen Fen Li, Ka Wai Kam, Simon T. Ko, Benjamin H.K. Yip, Alvin L. Young, Clement C. Tham, Li Jia Chen, Chi Pui Pang
Journal: Ophthalmology (2021)
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Authors: Koen B. Pouwels, Emma Pritchard, Philippa C. Matthews, Nicole Stoesser, David W. Eyre, Karina-Doris Vihta, Thomas House, Jodie Hay, John I. Bell, John N. Newton, Jeremy Farrar, Derrick Crook, Duncan Cook, Emma Rourke, Ruth Studley, Tim E. A. Peto, Ian Diamond, A. Sarah Walker
Journal: Nature Medicine (2021)

The effectiveness of the BNT162b2 and ChAdOx1 vaccines against new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections requires continuous re-evaluation, given the increasingly dominant B.1.617.2 (Delta) variant. In this study, we investigated the effectiveness of these vaccines in a large, community-based survey of randomly selected households across the United Kingdom. We found that the effectiveness of BNT162b2 and ChAdOx1 against infections (new polymerase chain reaction (PCR)-positive cases) with symptoms or high viral burden is reduced with the B.1.617.2 variant (absolute difference of 10-13% for BNT162b2 and 16% for ChAdOx1) compared to the B.1.1.7 (Alpha) variant. The effectiveness of two doses remains at least as great as protection afforded by prior natural infection. The dynamics of immunity after second doses differed significantly between BNT162b2 and ChAdOx1, with greater initial effectiveness against new PCR-positive cases but faster declines in protection against high viral burden and symptomatic infection with BNT162b2. There was no evidence that effectiveness varied by dosing interval, but protection was higher in vaccinated individuals after a prior infection and in younger adults. With B.1.617.2, infections occurring after two vaccinations had similar peak viral burden as those in unvaccinated individuals. SARS-CoV-2 vaccination still reduces new infections, but effectiveness and attenuation of peak viral burden are reduced with B.1.617.2.
P57.02 Integration of Systemic / Tumor PD-L1 as a Predictive Biomarker of Clinical Outcome in Advanced NSCLC Patients Treated With Anti-PD-(L)1 Agents
Authors: G. Anguera Palacios, C. Zamora Atenza, M. Riudavets Melià, L. Alserawan De Lamo, I. Sullivan, A. Barba Joaquín, J. Serra Lopez, M.A. Ortiz, M. Mulet, S. Vidal Alcorisa, M. Majem
Journal: Journal of Thoracic Oncology (2021)
MA13.03 Combination of Bevacizumab + Atezolizumab (A) Who Progressed On A In Pretreated NSCLC Patients: An Open-Label, Two-Stage, Phase II Trial
Authors: J. Lee, S. Park, H.A. Jung, J. Sun, S. Lee, J.S. Ahn, K. Park, M. Ahn
Journal: Journal of Thoracic Oncology (2021)
25P Early detection of breast cancer by liquid biopsy exploiting the DNA damage sensitivity (DDS)
Authors: R. Nussbaumer, J. Godau, R. Zanetti-Dällenbach, A. Faisst, O. Schicht, Z. Barekati, F. Staedtler, B. Woelnerhanssen
Journal: Annals of Oncology (2021)
Metabolic implications of pancreatic fat accumulation
Authors: Robert Wagner, Sabine S. Eckstein, Hajime Yamazaki, Felicia Gerst, Jürgen Machann, Benjamin Assad Jaghutriz, Annette Schürmann, Michele Solimena, Stephan Singer, Alfred Königsrainer, Andreas L. Birkenfeld, Hans-Ulrich Häring, Andreas Fritsche, Susanne Ullrich, Martin Heni
Journal: Nature Reviews Endocrinology (2021)
Emphasising the health benefits of climate change actions can make them more attractive to governments, says scientists
Authors: Jacqui Wise
Journal: BMJ (2021)

Emphasising the health benefits of climate change actions can make them more attractive to governments, says scientists Jacqui WiseTaking action on the climate crisis is a "win-win" as it will also produce positive impacts on health, according to a report from the Academy of Medical Sciences and the Royal Society.
MA06.01 Death From Intercurrent Disease After Proton- Versus Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer
Authors: N. Yegya-Raman, T. Kegelman, K. Kim, M. Kallan, W. Levin, K. Cengel, C. Langer, R. Cohen, C. Aggarwal, A. Singh, J. Bauml, S. Adusumalli, S. Denduluri, R. O'Quinn, B. Ky, A. Berman, S. Feigenberg
Journal: Journal of Thoracic Oncology (2021)
FP12.01 PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC
Authors: S. Lau, M. Rabindranath, J. Weiss, J. Li, S. Nirmalakumar, H. Ruff, S. Boerner, L.C. Tong, M. Tsao, P. Pal, M. Cabanero, Y.H. Hsu, A. Fung, A. Sacher, F.A. Shepherd, G. Liu, P. Bradbury, K. Yasufuku, K. Czarnecka-Kujawa, H.M. Ko, N. Leighl, J. Schwock
Journal: Journal of Thoracic Oncology (2021)
Antithrombotic Therapy for Outpatients With COVID-19
Authors: Otavio Berwanger
Journal: JAMA (2021)

Jean M. Connors, MD; Maria M. Brooks, PhD; Frank C. Sciurba, MD; Jerry A. Krishnan, MD; Joseph R. Bledsoe, MD; Andrei Kindzelski, MD; Amanda L. Baucom, MS; Bridget-Anne Kirwan, PhD; Heather Eng, BA; Deborah Martin, BA; Elaine Zaharris, BA; Brendan Everett, MD; Lauren Castro, MS; Nancy L. Shapiro, PharmD; Janet Y. Lin, MD; Peter C. Hou, MD; Carl J. Pepine, MD; Eileen Handberg, PhD; Daniel O. Haight, MD; Jason W. Wilson, MD; Sarah Majercik, MD; Zhuxuan Fu, MS; Yongqi Zhong, PhD; Vidya Venugopal, PhD; Scott Beach, PhD; Steve Wisniewski, PhD; Paul M Ridker, MD; ACTIV-4B Investigators; Scott Brakenridge; Eric Leifer; Andrea Troxel; Aldo Maggioni; Jeff Jacobson; Renato D. Lopes; Rob Mentz; Michelle Sholzberg; John H. Alexander; Donald Schreiber; Kabir Yadav; Anthony Vecchiarelli; Godson Oguchi; Lisa Merck; Victoria Altagracia; Antonio Gonzalez; Dominick Angiolillo; Fred Blind; John Cienki; Reinaldo Loy; Eddie Armas; Juvenal Martinez; Juan Ruiz Unger; Vishal Gulati; Temple Robinson; Claudia Kroker-Bode; Jason Wilson; David Beiser; Maggie Hagan; Jonathan Cohen; Sascha Goonewardena; Jeffrey Fletcher; Rowena Dolor; Thomas Jarrett; Vijay Patel; Ming-Li Wang; Nicole Acquisto; Anderson Mehrle; Khetpal Saangeeta; Nicholas Hanna; Hassan Abouhouli; Alexandra Weissman; Raman Purighalla; Nathan Bennett; Gregory Jay; David Barbham; TJ Milling; Dalla Abdelsayed; David McPherson; Patricia Salvato; Chukwumeka Orgwu; Anuradha Mundluru; Patti Olusola; Sarah Majercik; William Lewis
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Authors: Thierry Facon, Shaji K Kumar, Torben Plesner, Robert Z Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P Venner, Katja Weisel, Joseph R Mace, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Tahamtan Ahmadi, Jianping Wang, Rian Van Rampelbergh, Clarissa M Uhlar, Brenda Tromp, Maria Delioukina, Jessica Vermeulen, Saad Z Usmani
Journal: The Lancet Oncology (2021)
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study
Authors: Adam Penn-Nicholson, Sophia B Georghiou, Nelly Ciobanu, Mubin Kazi, Manpreet Bhalla, Anura David, Francesca Conradie, Morten Ruhwald, Valeriu Crudu, Camilla Rodrigues, Vithal Prasad Myneedu, Lesley Scott, Claudia M Denkinger, Samuel G Schumacher
Journal: The Lancet Infectious Diseases (2021)
Engineered IL‐10: A matter of affinity
Authors: Ruben Fernandez‐Santamaria, Pattraporn Satitsuksanoa
Journal: Allergy (2021)

Pleiotropic roles of IL-10. Immune cells including regulatory T cells and B cells, ILCregs, macrophages, and DCs produce IL-10, which exerts both anti-inflammatory and pro-inflammatory effects. In an anti-inflammatory state, IL-10 suppresses inflammatory signals from several immune cells. In a pro-inflammatory state, IL-10 can induce CD8+T cells to release IFN-γ and granzyme B. The underlying mechanism that defines anti-inflammatory and pro-inflammatory activities of IL-10 depends on the binding affinity of IL-10 to its receptors (IL-10Rα and IL-10Rβ). The dimerization of the IL-10 complex activates STAT1/STAT3 and diversifies the biological effects of IL-10. In hindsight, high-affinity to IL-10Rβ leads to both anti-inflammatory and pro-inflammatory activities while low-affinity to IL-10Rβ only induces anti-inflammatory functions.
Thermoresponsive polymeric dexamethasone prodrug for arthritis pain
Authors: Gang Zhao, Rongguo Ren, Xin Wei, Zhenshan Jia, Ningrong Chen, Yuanyuan Sun, Zhifeng Zhao, Subodh M. Lele, Haizhen A. Zhong, Mary B. Goldring, Steven R. Goldring, Dong Wang
Journal: Journal of Controlled Release (2021)
The Long, Slow Road to Lung Cancer Cure
Authors: James L. Mulshine, Bruce Pyenson
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal